[Click eStock] "Medical Imaging AI 'Vuno' Hits Bottom"

There is an analysis that the stock price of Vuno, an artificial intelligence (AI) video diagnostic company, has hit rock bottom.

On the 6th, Kiwoom Securities analyzed that although Vuno's fourth-quarter earnings announced the previous day fell short of market expectations, the stock price appears to be bottoming out due to the steady expansion of hospitals using its main products.

Vuno is the first company in Korea to introduce an AI medical device in 2018. It learns from a wide range of medical data such as X-rays, CT, MRI, and fundus images, and performs diagnosis to prediction.

Vuno's fourth-quarter earnings announced the previous day showed sales of 7.1 billion KRW and an operating loss of 2.7 billion KRW. Sales were 12.3% lower than the securities consensus, and the operating loss was about twice as large.

However, Minsoo Shin, an analyst at Kiwoom Securities, said, "Since the low point in November 2023, the market seems to recognize a market capitalization of 310 billion KRW as the bottom," adding, "It is important to confirm external growth domestically and internationally going forward." Vuno's market capitalization was 372.4 billion KRW the previous day.

According to Kiwoom Securities, the number of hospitals using Vuno's flagship AI-based cardiac arrest prediction medical device 'DeepCARS' increased steadily from 100 in the fourth quarter to 114 this quarter. It is also undergoing FDA approval procedures in the United States.

Last year, 'Chest X-ray,' which analyzes X-ray images to diagnose emergency diseases such as pneumothorax or pleural effusion, received FDA approval in the United States. Additionally, 'DeepBrain,' which analyzes brain MRI images to provide diagnosis of degenerative brain diseases such as Alzheimer's dementia and cognitive impairment, obtained U.S. FDA certification in 2023 and officially entered the U.S. market last year.